Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TD-0025 is a novel small-molecule drug developed primarily for the treatment of erectile dysfunction. It has also been referenced in the context of autoimmune diseases such as rheumatoid arthritis, though its main clinical development and trials have focused on urogenital indications. The drug has undergone phase 2/3 clinical studies comparing its efficacy to sildenafil citrate (Viagra) for erectile dysfunction. The mechanism of action is not explicitly detailed in public sources; however, as a small molecule intended for erectile dysfunction, it may act via pathways similar to phosphodiesterase type 5 (PDE5) inhibitors or other vasodilatory mechanisms. The compound was originally developed by Vietstar Biomedical Research[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TD-0025.